Aclaris Shares Trade Higher On Patent Win For Facial Redness Drug

Aclaris Therapeutics Inc ACRS shares were seeing some upward momentum Tuesday on the back of the announcement of a patent win.

What Happened

The U.S. Patent and Trademark Office has granted the company a patent — No. 10,335,391 — covering the methods to treat facial erythema associated with rosacea using Rhofade, or 1% oxymetazoline hydrochloride composition, Aclaris said Tuesday. 

Rhofade is the first alpha-1A adrenoreceptor agonist approved for the topical treatment of persistent facial erythema associated with rosacea in adults.

The company noted that the issued U.S. patent will be listed in the Orange Book for Rhofade. The patent is set to expire in June 2035.

Why It's Important

Persistent facial erythema associated with rosacea affects about 16 million people in the U.S., according to  Aclaris.

"Aclaris continues to expand its intellectual property estate and we are pleased to add a sixth Orange Book listable patent to the intellectual property portfolio covering Rhofade. This U.S. patent, together with the recently granted European patent, augment our strong worldwide intellectual property portfolio covering Rhofade," CEO Neal Walker said in a statement. 

Aclaris shares were up 6.98% at $2.30 at the time of publication Tuesday. 

Related Links:

The Week Ahead In Biotech: Conferences, Clinical Trial Readouts And Earnings

The Daily Biotech Pulse: Roche Presents Positive Hemlibra Data, Amgen's Tender Offer For Nuevolution Complete, Genmab Offering